No Single Biosimilars Model Fits Europe, Says Samsung Bioepis’ Ko
Brazil Is Also A Key Part Of The Firm’s Strategy
In the second part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out the firm’s strategy in Europe, as well as the importance of Brazil and China to its future plans.
